Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paroxetine - Novo Nordisk

Drug Profile

Paroxetine - Novo Nordisk

Alternative Names: Aropax; BRL 29060; BRL 29060A; Deroxat; Divarius; FG 7051; Frosinor; Motivan; NNC 207051; Paxil; Paxil CR; Seroxat; SI 211103; Tagonis

Latest Information Update: 31 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Developer GlaxoSmithKline; GlaxoSmithKline KK; Novo Nordisk; Scios; Vectura
  • Class Antidepressants; Anxiolytics; Benzodioxoles; Fluorobenzenes; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • Phase I Anxiety disorders

Most Recent Events

  • 26 Jul 2018 GlaxoSmithKline completes a phase I trial in Anxiety disorders (In volunteers) in China (PO) (NCT03329573)
  • 30 May 2018 Phase-I clinical trials in Anxiety disorders (In volunteers) in China (PO) (NCT03329573)
  • 06 Nov 2017 GlaxoSmithKline plans a phase I trial for Anxiety disorders (In volunteers) in June 2018 (PO) (NCT03329573)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top